GLAND · NSE
Gland Pharma Limited
₹3,331.9
+1.18% (+₹39)
Prev. close
₹3,292.9
Volume
3,00,572
Delivery %
70.9%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
5 analyst stances · last 90 days · one per analyst
Trackable
5 · 5 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Axis Direct recommends buying Gland Pharma with a target of ₹3,890, based on its strong earnings performance and rising …” | ETMarkets AnalysisETMarkets.com | Gland Pharma | PENDING | |
| “Motilal Oswal maintains a BUY stance on Gland Pharma, citing a target price of ₹3,690 that represents an upside of up to…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Gland Pharma Ltd | PENDING | |
| “Mahesh M Ojha, VP Research & Business Development at Kantilal Chhaganlal Securities, views Gland Pharma positively from …” | Mahesh M OjhaKantilal Chaganlal Securities | Gland Pharma | PENDING | |
| “Bullish on Gland Pharma for the next 1-2 weeks, recommending a buy at ₹3,088 with target prices of ₹3,400 and ₹3,500, an…” | Vishnu Kant UpadhyayMaster Capital Services | Gland Pharma Ltd | MISS | |
| “Recommends buying Gland Pharma at ₹2990, targeting ₹3220 with a stop loss at ₹2870. The stock shows a decisive breakout …” | Sumeet BagadiaChoice Equity Broking | Gland Pharma Ltd | MISS | |
| “Upgraded Gland Pharma to 'buy' from 'hold' on August 11, setting a target of ₹3,350 per share, which implies a 17.9% ups…” | Jefferies AnalysisJefferies | Gland Pharma | HIT | |
| “Maintained a 'Sell' rating on Gland Pharma with a target price of ₹1,675. While acknowledging the 39% YoY EBITDA growth …” | Goldman Sachs AnalysisGoldman Sachs Group Inc. | Gland Pharma | HIT | |
| “Retained a 'Buy' rating on Gland Pharma, raising the price target to ₹2,340, implying a 19% upside. The brokerage expect…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Gland Pharma Ltd | HIT | |
| “Bullish on Gland Pharma for intraday trading, recommending a buy at ₹1597.90 with a target of ₹1710 and a stop loss at ₹…” | Sumeet BagadiaChoice Equity Broking | Gland Pharma Ltd | MISS | |
| “Maintained an 'Underperform' rating on Gland Pharma, lowering the target price to ₹1,350 from ₹1,630. The brokerage cite…” | Jefferies AnalysisJefferies | Gland Pharma Ltd | MISS | |
| “Gland Pharma has broken out from a two-month consolidation range, indicating bullish momentum. Short-term traders with a…” | ETMarkets AnalysisETMarkets.com | Gland Pharma Ltd | MISS |
Market commentary · 4 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Upgraded Gland Pharma to 'Hold' from 'Underperform', raising the price target to ₹1,950 from ₹1,350. The firm believes G…” | Jefferies AnalysisJefferies | Gland Pharma | — | |
| “Maintains a BUY rating on Gland Pharma, expecting a CAGR of 14%, 20%, and 27% in revenue, EBITDA, and net profit over FY…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Gland Pharma | — | |
| “Upgraded Gland Pharma to Hold with a price target of ₹1,970, believing earnings have bottomed out, driven by a turnaroun…” | Jefferies AnalysisJefferies | Gland Pharma Ltd | — | |
| “Gland Pharma faces high risk from potential US tariffs as a CMO, with 54% US sales. A portion of its revenue comes from …” | Jefferies AnalysisJefferies | Gland Pharma | — |
Fundamentals
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, and neurological and central nervous system; blood related, ophthalmics and otologicals, cardiac, gastro-intestinal, and hormonal products; pain, neuromuscular blocking agents, and analgesics; respiratory and pulmonology; and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier preparation, and technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Srinivas Sadu
Headquarters
Hyderabad
Employees
4,332
Website
glandpharma.comExchange
View on NSE ↗Key stats
Market cap
₹52,417.35 Cr
P/E ratio (TTM)
46.4
Dividend yield
0.63%
EPS (TTM)
₹68.47
Beta (1Y · daily vs NIFTY 50)
0.58
Beta (5Y · monthly vs NIFTY 50)
0.28
Shares float
8.94 Cr
EPS · quarter ended Jun 2026
₹19.22
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
Inventory for FY21 and FY22: from the company's own statements, which the series had none for. Cash for FY21 and FY22: from the company's own statements, which the series had none for.
08 · Profit & Loss — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,597.65 Cr | ₹4,624.65 Cr | ₹3,865.06 Cr | ₹5,834.96 Cr | ₹5,830.11 Cr | ₹6,746.98 Cr | |
| ₹2,262.84 Cr | ₹3,006.09 Cr | ₹2,754.02 Cr | ₹4,702.42 Cr | ₹4,767.45 Cr | ₹5,258.05 Cr | |
Profit before exceptional item and tax (III)= (I-II) | ₹1,334.81 Cr† | ₹1,618.55 Cr | ₹1,111.04 Cr | ₹1,132.54 Cr† | ₹1,062.66 Cr | ₹1,488.93 Cr |
| ₹1,334.81 Cr | ₹1,618.55 Cr | ₹1,054.58 Cr | ₹1,132.54 Cr | ₹1,062.66 Cr | ₹1,464.58 Cr | |
| ₹337.85 Cr | ₹406.89 Cr | ₹273.54 Cr | ₹360.08 Cr | ₹364.13 Cr | ₹437.26 Cr | |
Profit for the year (VII)=(V-VI) | ₹996.96 Cr | ₹1,211.66 Cr | ₹781.04 Cr | ₹772.46 Cr | ₹698.53 Cr | ₹1,027.32 Cr |
| ₹87.20 L | ₹45.80 L | ₹1.44 Cr | ₹7.87 Cr | ₹-55.39 Cr | ₹-430.99 Cr | |
Total comprehensive income for the year, net of tax (IX) = (VII+VIII) | ₹996.09 Cr | ₹1,211.21 Cr | ₹779.61 Cr | ₹764.60 Cr | ₹753.91 Cr | ₹1,458.30 Cr |
Basic, computed on the basis of profit attributable to equity holders | 63.07 | 73.81 | — | — | — | — |
Diluted, computed on the basis of profit attributable to equity holders | 62.99 | 73.64 | — | — | — | — |
Owners of the Company | ₹996.96 Cr | ₹1,211.66 Cr | ₹781.04 Cr | ₹772.46 Cr | ₹698.53 Cr | ₹1,027.32 Cr |
Owners of the Company | ₹996.09 Cr | — | ₹779.61 Cr | ₹764.60 Cr | ₹753.91 Cr | ₹1,458.30 Cr |
Basic (₹) | — | — | 47.44 | 46.90 | 42.40 | 62.35 |
Diluted (₹) | — | — | 47.43 | 46.89 | 42.40 | 62.28 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| ₹6,496.08 Cr | ₹7,833.62 Cr | ₹8,777.54 Cr | ₹10,661.25 Cr | ₹11,224.92 Cr | |
| ₹6,496.08 Cr | ₹7,833.62 Cr | ₹8,777.54 Cr | ₹10,661.25 Cr | ₹11,224.92 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
‡ The company printed this figure on a line with no label (a bare subtotal under a block). Where the lines above add up to it, it is named after them; otherwise it is shown as “Unlabelled line”. The figure is the company’s own.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹604.93 Cr | ₹790.77 Cr | ₹363.97 Cr | ₹996.80 Cr | ₹914.73 Cr | ₹1,031.39 Cr | |
| ₹-1,524.00 Cr | ₹-1,002.62 Cr | ₹1,208.19 Cr | ₹-1,756.91 Cr | ₹1,704.74 Cr | ₹137.73 Cr | |
| ₹492.46 Cr | ₹318.82 Cr | ₹1,908.90 Cr | ₹357.09 Cr | ₹2,556.21 Cr | ₹3,359.11 Cr | |
| ₹492.46 Cr | ₹318.82 Cr | ₹1,908.90 Cr | — | — | — | |
Net cash (used in)/generated from financing activities (C) | — | — | ₹14.92 Cr | — | — | — |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22–Mar 24(7Q) | Jun 24–Mar 26(8Q) | Jun 26 |
|---|---|---|---|---|---|---|
| Promoter | 58.02% | 58.00% | 57.87% | 57.86% | 51.83% | 51.77% |
| Public | 41.97% | 42.00% | 42.13% | 42.14% | 48.17% | 48.23% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Gland Pharma Limited | ₹51,740.80 Cr | ₹3,159 | 45.8 | 5.00 | 9.9% | 0.03 | +14.7% | +65.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Gland Pharma Holders Are Up 93% And Here Is What They Saw
Gland Pharma’s shares have risen about 93% year‑to‑date, reaching roughly ₹3,293 from ₹1,715 at the start of 2026. The rally follows a U.S. FDA approval for a methylprednisolone injectable, which helped lift quarterly revenue to ₹18.34 billion and improve net margin to 15.9%, prompting optimistic fair‑value estimates despite some analysts warning of capacity‑utilisation risks.
LINK PHARMA Share Price Today Up 11%
Gland Pharma shares rose about 80% over the past twelve months, making it one of the top gainers in the BSE Healthcare index. The surge contrasts with broader market trends, as the BSE Healthcare index gained 17.8% while the BSE Sensex fell 3.2% in the same period.